BIOGEN INC. (BIIB) Options Risk Score
Real-time risk analysis for BIIB options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full BIIB options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan BIIB Now — Free →
Is it risky to sell options on BIOGEN INC. (BIIB) right now?
For a 4-week expiry, BIOGEN INC. (BIIB) carries an options catalyst-risk score of 80 out of 100 (HIGH). That score is driven by 13 recent news items, 2 active legal filings and 12 clinical-trial catalysts falling inside the 4-week window. On TickerRisk's scale 70 and above is HIGH, so a known event is scheduled inside this window — selling premium on BIIB here is a bet on that event rather than on time decay. The score measures scheduled event exposure, not which way the stock will move.
BIIB shows an IV Rank of 75 — implied volatility is near the top of its own one-year range, so BIIB options are historically expensive, which favours premium-selling strategies, with a current implied volatility of about 45%. IV Rank is the most useful figure for deciding whether to sell or buy premium on BIIB.
BIIB's next earnings date is 2026-07-29, outside the near-term options window; the stock has moved down 3.0% recently.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer